Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06031441 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06031441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06031441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 27, 2023
Completion date
March 3, 2027
Enrollment
65 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumors, metastatic solid tumors, recurrent solid tumors